Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SYT-510

            Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $26.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 20, 2021

            Details:

            This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.